Bronfman E.L. Rothschild L.P. lifted its position in Johnson & Johnson (NYSE:JNJ) by 23.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,225 shares of the company’s stock after acquiring an additional 8,218 shares during the period. Johnson & Johnson accounts for 0.7% of Bronfman E.L. Rothschild L.P.’s holdings, making the stock its 25th largest position. Bronfman E.L. Rothschild L.P.’s holdings in Johnson & Johnson were worth $5,718,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of JNJ. State Street Corp boosted its stake in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares during the last quarter. Harbour Capital Advisors LLC boosted its stake in Johnson & Johnson by 13,327.8% during the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock worth $18,909,000 after buying an additional 2,482,843 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Johnson & Johnson by 29.1% during the second quarter. Principal Financial Group Inc. now owns 5,809,262 shares of the company’s stock worth $768,508,000 after buying an additional 1,310,587 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in Johnson & Johnson by 33.9% during the second quarter. Canada Pension Plan Investment Board now owns 4,696,566 shares of the company’s stock worth $621,309,000 after buying an additional 1,189,900 shares during the last quarter. Finally, Bank of Nova Scotia boosted its stake in Johnson & Johnson by 94.5% during the first quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after buying an additional 569,313 shares during the last quarter. 65.90% of the stock is currently owned by hedge funds and other institutional investors.

JNJ has been the topic of a number of recent research reports. Cowen reissued an “outperform” rating and set a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. UBS reissued a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research note on Thursday, August 31st. Jefferies Group boosted their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $144.59.

Shares of Johnson & Johnson (NYSE:JNJ) traded up $1.40 during trading on Wednesday, hitting $141.07. The stock had a trading volume of 1,120,404 shares, compared to its average volume of 5,877,685. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35. The firm has a market cap of $373,453.13, a price-to-earnings ratio of 19.47, a PEG ratio of 2.83 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the prior year, the company posted $1.68 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.38%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

ILLEGAL ACTIVITY WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/06/johnson-johnson-jnj-shares-bought-by-bronfman-e-l-rothschild-l-p.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.